Improvement of DAS-28 ESR score in Egyptian children and adolescents with juvenile idiopathic arthritis treated with etanercept
المؤلفون المشاركون
Shahin, Wala Abd al-Qasim
Uthman, Hibah Tahir
Yusuf, Minnat Allah Ala al-Din
Afifi, Rasha Abd al-Rauf Abd al-Aziz
المصدر
Egyptian Pediatric Association Gazette
العدد
المجلد 65، العدد 2 (31 يوليو/تموز 2017)، ص ص. 33-37، 5ص.
الناشر
تاريخ النشر
2017-07-31
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
العلوم الاجتماعية (متداخلة التخصصات)
الطب البشري
الموضوعات
الملخص EN
Aim of study : To assess the efficacy and safety of using anti-tumor necrosis factor-a (TNF-a), Etanercept (ETN) in treatment of children and adolescents with Juvenile Idiopathic arthritis (JIA).
Patients and methods: This retrospective cohort study included 18 children and adolescents who were diagnosed as JIA and treated with anti-tumor necrosis factor-a (TNF-a), ETN for at least 6 months due to failure of synthetic disease-modifying antirheumatic drugs (sDMARDS) as methotrexate (MTX).
Before starting ETN treatment, all patients were receiving MTX in addition to non-steroidal antiinflammatory drugs (NSAIDs).
Other medications used were Prednisolone, Leflunamide and Hydroxychloroquine.
As per recommendations of the European League Against Rheumatism (EULAR), failure of these DMARDs is an indication to start biological DMARDs.
Anti TNF-a, mainly ETN is one of the most commonly used biological DMARDs in treating JIA.
Clinical scoring using DAS28-ESR score was done for all patients at time of enrollment, 3 months and 6 months after starting ETN.
The effect of different clinical and laboratory variables on the outcome of ETN treatment was assessed.
Results: There was statistically significant improvement in DAS28-ESR after 3 months of treatment (p = 0.001) and after 6 months (p = 0.049).
There was no statistically significant difference in DAS-28 score between males and females, patients younger than 10 years and patients older than 10 years, neither at onset nor at 6 months’ follow up.
Similarly, the duration of illness before starting ETN did not affect DAS28 score at 6 months of treatment.
Conclusion: ETN treatment of JIA children and adolescents demonstrated safety and efficacy in clinical improvement of DAS28-ESR score at 3 and 6 months of treatment.
However, further studies on a bigger number of patients, longer duration and using different biological agents are needed.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Afifi, Rasha Abd al-Rauf Abd al-Aziz& Uthman, Hibah Tahir& Shahin, Wala Abd al-Qasim& Yusuf, Minnat Allah Ala al-Din. 2017. Improvement of DAS-28 ESR score in Egyptian children and adolescents with juvenile idiopathic arthritis treated with etanercept. Egyptian Pediatric Association Gazette،Vol. 65, no. 2, pp.33-37.
https://search.emarefa.net/detail/BIM-761250
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Afifi, Rasha Abd al-Rauf Abd al-Aziz…[et al.]. Improvement of DAS-28 ESR score in Egyptian children and adolescents with juvenile idiopathic arthritis treated with etanercept. Egyptian Pediatric Association Gazette Vol. 65, no. 2 (Jul. 2017), pp.33-37.
https://search.emarefa.net/detail/BIM-761250
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Afifi, Rasha Abd al-Rauf Abd al-Aziz& Uthman, Hibah Tahir& Shahin, Wala Abd al-Qasim& Yusuf, Minnat Allah Ala al-Din. Improvement of DAS-28 ESR score in Egyptian children and adolescents with juvenile idiopathic arthritis treated with etanercept. Egyptian Pediatric Association Gazette. 2017. Vol. 65, no. 2, pp.33-37.
https://search.emarefa.net/detail/BIM-761250
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 37
رقم السجل
BIM-761250
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر